ACTG 185--PHASE III/HYPERIMMUNE ANTI-HIV IV IMMUNE GLOBULIN/MATERNAL-FETAL TRANS

ACTG 185--III期/超免疫抗HIV IV免疫球蛋白/母胎反式

• 批准号: 6122084
• 负责人: RUSSELL B. VAN DYKE
• 金额: $ 1.12万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-07-19 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6122084
• 关键词: AIDS education /prevention; AIDS therapy; HIV infections; antiviral antibody; chemoprevention; clinical research; combination therapy; drug administration rate /duration; drug screening /evaluation; embryo /fetus chemotherapy; human pregnant subject; human subject; human therapy evaluation; hyperimmunization; immunoglobulins; immunotherapy; newborn human (0-6 weeks); vertical transmission; zidovudine

Randomized, controlled trial to evaluate the efficacy, safety and tolerance of the combination of HIV hyperimmune globulin (HIVIG) administered during pregnancy and to the newborn within 12 hours of birth and ZDV administered intrapartum and to the newborn for six weeks following birth - compared to IVIG and ZDV administered similarly, for the reduction of vertical HIV transmission in HIV infected pregnant women.

这是一项随机对照试验，旨在评估在怀孕期间和出生后12小时内给新生儿注射艾滋病毒高免疫球蛋白(HIVIG)，以及在分娩期间和新生儿出生后六周内注射ZDV的组合在减少艾滋病毒感染孕妇中艾滋病毒垂直传播方面的有效性、安全性和耐受性。